The selective ERβ agonist DPN inhibits growth of Granta-519 MCL tumors in vivo. (A) The expression of ERα and ERβ mRNA in Granta-519 MCL was measured by quantitative real-time PCR. (B) Male NOD-SCID mice were subcutaneously grafted with 15 × 106 Granta-519 MCL cells. Starting from day 9 after tumor cell grafting, animals were treated subcutaneously daily with the ERβ-selective agonist DPN (12.5 μmol/kg per day) (▪) or vehicle (●). Both groups consisted of 5 mice. (C) Ki67 expression in sectioned Granta-519 MCL tumors from mice was significantly lower in tumors from mice treated with DPN than in those from vehicle-treated control mice. Treatment with DPN also inhibited the expression of BAFF (D) and GRB7 (E) in Granta-519 MCL lymphomas. For vehicle vs DPN: *P < .05, **P < .01, and ***P < .001. Data are representative of at least 2 independent experiments.
